Cargando…

Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity

Detalles Bibliográficos
Autores principales:	Fraunhoffer, Nicolas Alejandro, Abuelafia, Analía Meilerman, Chanez, Brice, Bigonnet, Martin, Gayet, Odile, Roques, Julie, Chuluyan, Eduardo, Dusetti, Nelson, Iovanna, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648386/ https://www.ncbi.nlm.nih.gov/pubmed/36178036 http://dx.doi.org/10.1002/cac2.12365

Ejemplares similares

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction
por: Fraunhoffer, Nicolas A., et al.
Publicado: (2022)

Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool
por: Fraunhoffer, Nicolas A., et al.
Publicado: (2022)

Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma
por: Huang, Can, et al.
Publicado: (2019)

Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers
por: El Kaoutari, Abdessamad, et al.
Publicado: (2023)

Long-term apoptosis-related protein expression in the diabetic mouse ovary
por: Fraunhoffer, Nicolas A., et al.
Publicado: (2018)

Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
por: Bian, Benjamin, et al.
Publicado: (2019)

Induction of Apoptosis in Human Pancreatic Cancer Stem Cells by the Endoplasmic Reticulum-Targeted Alkylphospholipid Analog Edelfosine and Potentiation by Autophagy Inhibition
por: Gajate, Consuelo, et al.
Publicado: (2021)

Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells
por: Fraunhoffer, Nicolas A., et al.
Publicado: (2023)

Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance
por: Kaoutari, Abdessamad El, et al.
Publicado: (2021)

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
por: Hoare, Owen, et al.
Publicado: (2021)

Identification of germ cell-specific VASA and IFITM3 proteins in human ovarian endometriosis
por: Fraunhoffer, Nicolas A., et al.
Publicado: (2015)

Expression of POU2F3 Transcription Factor Control Inflammation, Immunological Recruitment and Metastasis of Pancreatic Cancer in Mice
por: Bintz, Jennifer, et al.
Publicado: (2020)

E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments
por: Lan, Wenjun, et al.
Publicado: (2018)

A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis
por: Mohamed Abd-El-Halim, Yousra, et al.
Publicado: (2021)

Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer
por: Nicolle, Rémy, et al.
Publicado: (2020)

Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer
por: Nicolle, R., et al.
Publicado: (2021)

Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome
por: Juiz, Natalia Anahi, et al.
Publicado: (2019)

Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine
por: Lomberk, Gwen, et al.
Publicado: (2019)

A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT
por: Barraud, Marine, et al.
Publicado: (2016)

Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer
por: Liu, Juan, et al.
Publicado: (2021)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo
por: Reyes-Castellanos, Gabriela, et al.
Publicado: (2023)

Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer
por: Masoud, Rawand, et al.
Publicado: (2020)

Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma
por: Molejon, Maria Inés, et al.
Publicado: (2015)

Selection of Intracellular Single-Domain Antibodies Targeting the HIV-1 Vpr Protein by Cytoplasmic Yeast Two-Hybrid System
por: Matz, Julie, et al.
Publicado: (2014)

The Functional Landscape of Hsp27 Reveals New Cellular Processes such as DNA Repair and Alternative Splicing and Proposes Novel Anticancer Targets
por: Katsogiannou, Maria, et al.
Publicado: (2014)

Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts
por: Bian, Benjamin, et al.
Publicado: (2017)

Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma
por: Molejon, María Inés, et al.
Publicado: (2018)

Assessment of biological effect of nab-paclitaxel combined with gemcitabine, using contrast enhanced ultrasonography and elastography, in advanced pancreatic ductal carcinoma: A single-center pilot study
por: Dahel, Yanis, et al.
Publicado: (2023)

Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
por: Lomberk, Gwen, et al.
Publicado: (2018)

Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts
por: Nicolle, Rémy, et al.
Publicado: (2017)

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
por: Bian, Benjamin, et al.
Publicado: (2019)

A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor
por: Gayet, Odile, et al.
Publicado: (2014)

OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer
por: Baylot, V, et al.
Publicado: (2011)

Data on biosynthesis of BPAF glucuronide, enzyme kinetics of BPAF glucuronidation, and molecular modeling
por: Gramec Skledar, Darja, et al.
Publicado: (2018)

Targeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrence
por: Molejon, Maria Inés, et al.
Publicado: (2015)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide
por: de Hoogd, Sjoerd, et al.
Publicado: (2017)

Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2’,2’‐difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer
por: Garcia‐Cremades, Maria, et al.
Publicado: (2020)

Glucuronidation of drugs in humanized UDP-glucuronosyltransferase 1 mice: Similarity with glucuronidation in human liver microsomes
por: Kutsuno, Yuki, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d63sfkv2jie5ph14me0btl0ng2